Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UCB's Total Liabilities for the quarter that ended in Jun. 2026 was MXN180,501 Mil.
UCB's quarterly Total Liabilities
declined
from Jun. 2025 (MXN162,947.51 Mil) to Dec. 2025 (MXN153,723.14 Mil) but then
increased
from Dec. 2025 (MXN153,723.14 Mil) to Jun. 2026 (MXN180,500.66 Mil).
UCB's annual Total Liabilities
increased
from Dec. 2023 (MXN121,503.78 Mil) to Dec. 2024 (MXN159,813.63 Mil) but then
declined
from Dec. 2024 (MXN159,813.63 Mil) to Dec. 2025 (MXN153,723.14 Mil).
The historical data trend for UCB's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
UCB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN180,501 Mil mean?
UCB (MEX:UCBN) has a Total Liabilities of MXN180,501 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for UCB and its competitors.
Is UCB's Total Liabilities too high?
UCB's current Total Liabilities is MXN180,501 Mil. Overall, UCB has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does UCB's Total Liabilities compare to VRTX and REGN?
UCB's Total Liabilities of MXN180,501 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for UCB and its competitors. UCB's current Total Liabilities is MXN180,501 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
UCB (MEX:UCBN) has a current Total Liabilities of MXN180,501 Mil. The stock's GF Value™ is MXN1,905.79, compared to a current price of MXN1,692.27 — trading 11.2% below its estimated fair value. The current Total Liabilities is MXN180,501 Mil. UCB's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For UCB (MEX:UCBN), the current Total Liabilities is MXN180,501 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (MEX:UCBN) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be undervalued.
The current stock price of MXN1,692.27 is trading 11.2% below its estimated GF Value™ of MXN1,905.79.
Key valuation signals for MEX:UCBN:
Total Liabilities: MXN180,501 Mil
GF Value™: MXN1,905.79 vs. price of MXN1,692.27 (11.2% below fair value)
No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
95GF Score
Get the complete analysis for MEX:UCBN
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:UCBN has been successfully added to your 
